RARE

16.6303.43%
MA

Michael A. Narachi

Independent Director

Mr. Michael A. Narachi, also known as Mike, M.S., M.B.A, served as Chief Executive Officer and President of Orexigen Therapeutics, Inc. since March 2009 until July 27, 2018. Mr. Narachi serves as President and Chief Executive Officer and Director of CODA Biotherapeutics, Inc. Mr. Narachi served as interim Chief Financial Officer of Orexigen Therapeutics, Inc. since December 11, 2015. He has biotechnology and pharmaceutical experience in clinical development, commercialization, strategic business development and planning at Orexigen. He was a member of various boards of directors in the biotechnology and pharmaceutical sectors. He served as the Chief Executive Officer, Chairman and President of REN Pharmaceuticals Inc. since November 2006 until March 2009. He served as an Officer and Vice President of Amgen Inc. until retirement in 2004 and also served as General Manager for Amgen's Anemia Business from 1999 to 2003. He led Amgen Inc.'s integrated medical, marketing and sales team whose chief aim was to eliminate anemia and its complications. He joined Amgen in July 1984 as a Molecular Biology Research Associate. He held various positions throughout the Amgen over a many year career including Product Development Team Leader for NEUPOGEN(R), Director of Clinical Operations in Thousand Oaks, CA of Cambridge, UK, Vice President of Development and Representative Director of Amgen Japan, Head of Corporate Strategic Planning, Chief Operations Officer of Amgen Biopharma and Vice President of Licensing and Business Development. He served as the Chairman at Celladon Corporation since October 2013 until March 2016. Mr. Narachi has been the Chairman of SinusPharma, Inc. since September 2004. He served as the Chairman of AMAG Pharmaceuticals, Inc. from October 2009 to April 16, 2014. He served as an Executive Chairman of Naryx Pharma, Inc. He has been an Independent Director of Ultragenyx Pharmaceutical Inc. since February 20, 2015. He served as a Director of Orexigen Therapeutics, Inc. since March 2009 until July 27, 2018. He served as a Non-Employee Director of Celladon Corporation. Mr. Narachi serves as chair of the Emerging Companies Section Governing Board of BIO, the Biotechnology Innovation Organization and previously served as a member of the Board of Directors of PhRMA, the Pharmaceutical Research and Manufacturers of America. He served as Director at Eiger BioPharmaceuticals, Inc. until March 22, 2016. He served as a Director of AMAG Pharmaceuticals Inc. (formerly, Advanced Magnetics Inc.) since November 8, 2006 until May 22, 2014. He served as a Representative Director of Amgen Japan. Mr. Narachi received a B.S. in Biology and an M.A. in Biology and Genetics from the University of California at Davis in 1984. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.

Positions